News release - Tobacco Grow Trial ResultsCO2 GRO Inc. Announces Positive Tobacco Grow Trial Results for a Biopharma Company TORONTO, ON / ACCESSWIRE / September 24, 2019 / Toronto based CO2 GRO Inc. ("GROW") (TSX-V:GROW, OTCQB:BLONF, Frankfurt:4021) is excited to announce statistically significant positive results from a tobacco plant R&D grow trial for a Biopharma company ("Customer"). The Customer, who has requested not to be named as per the non-disclosure agreement signed by the parties, currently produces and sells a human drug that is extracted from inoculating young tobacco plant leaves with a specific bacterium. The Customer also has a pipeline of other human drugs in development that will be produced using the same plant inoculation process. The trial was conducted by the University of Guelph. Pre-inoculated tobacco plants were grown using GROW's CO2 Delivery Solutions versus a control of no CO2. The results below once again confirm CO2 Delivery Solutions' ability to significantly enhance the growth of leafy plants: Measure Percentage Increase/Decrease Height 48.9% Wet Weight 112% Dry Weight 133% Leaf Area 147% Numerous other Biopharma companies around the world are producing high value medicines and vaccines extracted from inoculated or genetically modified tobacco, potato or other leaves. As this 2018 article from TechnologyWorks.com describes, tobacco plants can become "Organic Mini Factories Producing Vaccines and New Drugs". John Archibald, CEO, stated "The results once again underscore the effectiveness of CO2 Delivery Solutions on a variety of plants. Our Biopharma customer will now conduct a grow trial on post-inoculated tobacco plants using CO2 Delivery Solutions to assess the impact on increased medicinal content in the plant. Upon a successful post-inoculation trial, the discussion with the Customer will progress towards a Commercial Installation at their facility, and open the market to other similar customers in the industry."